National Bank of Canada
VKTX icon

National Bank of Canada’s Viking Therapeutics VKTX Stock Holding History

National Bank of Canada’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$3.52K – 3213
2025
Q4 		$3.52K Buy
100
+50
+100% +$1.77K ﹤0.01% 2493
2025
Q3 		$1.31K Sell
50
-72
-59% -$2.15K ﹤0.01% 2625
2025
Q2 		$3.23K Sell
122
-319,423
-100% -$8.41M ﹤0.01% 2565
2025
Q1 		$7.72M Buy
319,545
+317,765
+17,852% +$10M 0.01% 793
2024
Q4 		$71.6K Sell
1,780
-1,768
-50% -$101K ﹤0.01% 1837
2024
Q3 		$225K Buy
3,548
+3,398
+2,265% +$199K ﹤0.01% 1358
2024
Q2 		$8.27K Hold
150
– – ﹤0.01% 2167
2024
Q1 		$11K Buy
+150
New +$6.67K ﹤0.01% 2150
2022
Q3 		– Sell
-1,300
Closed -$4K – 2906
2022
Q2 		$4K Hold
1,300
– – ﹤0.01% 2497
2022
Q1 		$4K Hold
1,300
– – ﹤0.01% 2612
2021
Q4 		$6K Buy
+1,300
New +$7.29K ﹤0.01% 2513

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

National Bank of Canada's VKTX Position: Q1 2026 in Review

National Bank of Canada sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 100 shares — an estimated $3.52K sold.

National Bank of Canada first reported a position in VKTX in Q4 2021 and held it in 11 quarters. The position peaked at $7.72M in Q1 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • National Bank of Canada reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • National Bank of Canada sold 100 Viking Therapeutics shares in Q1 2026, an estimated $3.52K.
  • National Bank of Canada first reported a position in Viking Therapeutics in Q4 2021 and held it in 11 quarters.
  • National Bank of Canada's Viking Therapeutics position peaked at $7.72M in Q1 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.